Recognizing Excellence in Cancer Immunotherapy: 2026 SITC Annual Award Winners Announced
Celebrating Achievements in Cancer Immunotherapy
The Society for Immunotherapy of Cancer (SITC) proudly announces the recipients of its 2026 Annual Awards, recognizing outstanding individuals whose leadership and groundbreaking achievements have significantly advanced the field of cancer immunotherapy. This prestigious event takes place during the SITC 2026 Annual Meeting, scheduled from November 4 to 8, 2026, at the Phoenix Convention Center in Phoenix, Arizona, as well as virtually, allowing participation from a global audience.
Honoring Exceptional Contributions
SITC Vice President, Dr. Sandra Demaria, emphasizes the extraordinary insights and dedication of this year’s awardees, stating, "The remarkable achievements of this year's award recipients reflect the innovation, collaboration, and dedication that continue to transform cancer immunotherapy." The awards celebrate those who significantly impact scientific discovery and enhance patient outcomes in cancer therapy, furthering the SITC's mission. This year, the following individuals have been honored:
- - 2027 Richard V. Smalley Memorial Award and Lectureship: Dr. Hans-Georg Rammensee, University of Tübingen.
- - 2026 Richard V. Smalley Memorial Award and Lectureship: Dr. Catherine J. Wu, Dana-Farber Cancer Institute.
- - 2026 SITC Lifetime Achievement Award: Dr. Paolo Antonio Ascierto, Università degli Studi di Napoli Federico II, Naples, Italy.
- - 2026 Tara Withington Public Service Award: Samantha Guild, JD, AIM at Melanoma Foundation.
- - 2026 Pedro J. Romero Service to JITC Award: Dr. Claudia Palena, Center for Cancer Research, National Cancer Institute.
These award recipients are acknowledged for their exceptional contributions, which not only advance their individual research but also serve to enhance the collective knowledge and application of immunotherapy globally. Their longstanding commitment and tireless efforts play a critical role in developing better treatment protocols and improving overall patient care.
SITC's Legacy and Future Aspirations
Founded in 1984, SITC is a non-profit organization dedicated to improving outcomes for cancer patients by promoting the development, science, and utilization of cancer immunotherapy and tumor immunology. The Society comprises a diverse network of influential scientists, healthcare providers, and industry professionals who collaborate to push the boundaries of cancer treatment. By fostering educational initiatives and scientific discourse, SITC aims to create a world where the word "cure" becomes a reality for patients battling cancer.
As part of its ongoing commitment to excellence, SITC invites nominations for next year's awards in the spring, continuing the tradition of recognizing significant contributions to immunotherapy research and practice. To learn more about the Annual Awards and how to be involved, please visit SITC's website.
This recognition of outstanding leaders in the field exemplifies not just individual achievements but also the collective effort in transforming the landscape of cancer treatment. As the SITC looks forward to this year's meeting, it celebrates the spirit of collaboration and innovative thinking that propels the science of immunotherapy forward.
To stay connected with SITC's upcoming events, educational resources, and the latest in cancer immunotherapy developments, follow the organization on various social media platforms, including X, LinkedIn, Facebook, Instagram, and YouTube. Join the conversation and be part of the movement to empower patients with better treatment options for cancer.
For further information and to view past award recipients, please visit SITC's official website.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.